Business, energy, technology, markets and global industry news from Business News Today

structural heart disease

PharmaDeviceNews structural heart disease
Representative image: A bioprosthetic aortic valve in a surgical setting highlights the growing focus on long-term heart valve durability as Edwards Lifesciences’ 10-year RESILIA tissue data sharpen the debate over lifetime valve planning in aortic stenosis care.
Medical Devices & Diagnostics

Edwards Lifesciences’ RESILIA data may shift the valve debate, but not without caveats

Valve durability is becoming a lifetime-care question. Edwards Lifesciences’ 10-year RESILIA data raise the stakes for heart teams.

Read More
Edwards Lifesciences advances structural heart care with EVOQUE tricuspid valve replacement
Medical Devices & Diagnostics

Why Edwards Lifesciences is betting on transcatheter replacement to solve tricuspid regurgitation

Find out how transcatheter tricuspid valve replacement is reshaping treatment options for severe regurgitation and what clinicians are watching next.

Read More
Trisol’s valve trial shows strong early outcomes in patients deemed too high risk for surgery
Medical Devices & Diagnostics

Can Trisol’s TTVR platform solve the right heart puzzle in tricuspid regurgitation care?

Trisol’s valve shows early safety and efficacy in high-risk TR patients. Explore what this means for the future of transcatheter tricuspid therapies.

Read More